000			03687nam a22004095i 4500
001			84508
003			ES-MaUEC
005			20230207040427.0
007			cr nn 008mamaa
008			151118s2016 fr | s |||| 0|eng d
020			_a9782817804927
040			_aES-MaUEC
050		4	_aRC270.8 _b2016 EB
245	1	0	_amTOR Inhibition for Cancer Therapy: Past, Present and Future _cedited by Monica Mita, Alain Mita, Eric K Rowinsky
250			_a1st ed.
260			_aParis _bSpringer Paris _c2016
300			_a1 recurso en línea (VI, 300 páginas) _b16 ilustraciones, 13 ilustraciones en color
336			_aTexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
505	0		_aForward -- Past -- mTOR inhibitors: a little bit of history -- Present -- The mTOR pathway -- The evolving role of mTOR inhibitors in renal cell carcinoma -- The role of mTOR inhibitors in breast cancer -- The role of mTOR inhibitors in neuroendocrine tumors -- New indications of mTOR inhibitors in rare tumors -- The role of mTOR inhibitors in the treatment of hematological malignancies -- The clinical pharmacology and toxicity profile of rapalogs -- Resistance to mTOR inhibitors -- Rational combinations of mTOR inhibitors as anticancer strategies -- Future -- Predictive biomarkers of response to mTOR inhibitors -- The potential future indication of rapamycin analogs for the treatment of other solid tumors -- mTOR inhibition beyond rapalogs -- mTOR, aging and cancer: the missing link? -- New study design for mTOR inhibitors and other biological agents -- Future directions for the development of mTOR inhibitors.
520	3		_aThis book describes the challenges involved in developing mTOR inhibitors for cancer treatment, starting with an in-depth examination of their molecular mechanism of action, with emphasis on the class side-effects, efficacy and mechanisms of resistance, as well as on promising novel directions for their development, including novel compounds and rational combinations with other anti-neoplastic drugs. Over the last 10 years, inhibitors of mTOR have emerged as a major class of anticancer drugs. Two rapamycin analogs are currently approved for the treatment of renal cell carcinoma, and it is estimated that a variety of other tumor types could benefit from mTOR inhibition, with numerous clinical trials (including pivotal registration trials) already underway. Second-generation small-molecule inhibitors of the pathway have also shown promise in terms of their superior tolerability and efficacy and are undergoing extensive clinical evaluation, with an estimated 30+ compounds currently under evaluation.
710	2		_aSpringerLink (Online service) _0Local _9106996
942			_2lcc _cLE
650		7	_aMedicina _0comprobar BNE19900959047 _2embne _9405021
650		7	_aBiología molecular _0comprobar BNE19900968373 _2embne _9139103
650		7	_9140122 _aHematología _0comprobar BNE19900981064 _2embne
700	1		_aMita, Monica. _eeditor literario _996739 _0Local
700	1		_aMita, Alain. _eeditor literario _996740 _0Local
700	1		_aRowinsky, Eric K. _eeditor literario _996741 _0Local
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-2-8178-0492-7 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
901			_ai9782817804927
907			_a.b12937861 _b10-10-17 _c21-11-16
988			_aSpringer_Medicine_2016
998			_am _a_alco _a_vill _b - - _cm _dz _e- _feng _gfr _h0
945			_aRC270.8 M767 2016 EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i11582510 _z06-04-17
999			_c84508 _d84508 _x1